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The cannabinoid type 1 (CB1) receptor is widely distributed in the brain and peripheral
organs where it regulates cellular functions and metabolism. In the brain, CB1 is mainly
localized on presynaptic axon terminals but is also found on mitochondria (mtCB1),
where it regulates cellular respiration and energy production. Likewise, CB1 is localized
on muscle mitochondria, but very little is known about it. The aim of this study was to
further investigate in detail the distribution and functional role of mtCB1 in three different
striated muscles. Immunoelectron microscopy for CB1 was used in skeletal muscles
(gastrocnemius and rectus abdominis) and myocardium from wild-type and CB1-KO
mice. Functional assessments were performed in mitochondria purified from the heart
of the mice and the mitochondrial oxygen consumption upon application of different
acute delta-9-tetrahydrocannabinol ( 91 -THC) concentrations (100 nM or 200 nM) was
monitored. About 26% of the mitochondrial profiles in gastrocnemius, 22% in the rectus
abdominis and 17% in the myocardium expressed CB1. Furthermore, the proportion
of mtCB1 versus total CB1 immunoparticles was about 60% in the gastrocnemius,
55% in the rectus abdominis and 78% in the myocardium. Importantly, the CB1
immunolabeling pattern disappeared in muscles ofCB1-KOmice. Functionally, acute 100
nM or 200 nM THC treatment specifically decreased mitochondria coupled respiration
between 12 and 15% in wild-type isolated mitochondria of myocardial muscles but no
significant difference was noticed between THC treated and vehicle in mitochondria
isolated from CB1-KO heart. Furthermore, gene expression of key enzymes involved in
pyruvate synthesis, tricarboxylic acid (TCA) cycle andmitochondrial respiratory chain was
evaluated in the striated muscle of CB1-WT and CB1-KO. CB1-KO showed an increase
in the gene expression of Eno3, Pkm2, and Pdha1, suggesting an increased production
of pyruvate. In contrast, no significant difference was observed in the Sdha and Cox4i1
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expression, between CB1-WT and CB1-KO. In conclusion, CB1 receptors in skeletal and
myocardial muscles are predominantly localized in mitochondria. The activation of mtCB1
receptors may participate in the mitochondrial regulation of the oxidative activity probably
through the relevant enzymes implicated in the pyruvate metabolism, a main substrate
for TCA activity.
Keywords: endocannabinoid system, intracellular receptors, striated muscle, mitochondrial respiration,
metabolism, immunocytochemistry
INTRODUCTION
The endocannabinoid system is broadly distributed in
the central nervous system (Freund et al., 2003; Castillo
et al., 2012; Kano, 2014). This modulatory system is
made up of the endocannabinoids (the two main are
N-arachidonoylethanolamine or anandamide and 2-
arachidonoylglycerol, 2-AG) (Mechoulam et al., 1995; Sugiura
et al., 1995) as well as their biosynthetic and degrading enzymes
(Freund et al., 2003; Di Marzo et al., 2015) and transport systems
(Fu et al., 2011). Most of the cannabinoid and endocannabinoid
effects are mediated by the G protein-coupled CB1 and CB2
receptors (Di Marzo et al., 2015). CB1 receptors are also
distributed in the periphery, e.g., skeletal muscle, liver, pancreas,
and adipose tissue, where they are involved in cellular functions
and energy metabolism (Piomelli, 2003; Pagotto et al., 2006;
Silvestri and Di Marzo, 2013; Mazier et al., 2015). Anatomically,
the protein and mRNA expression of CB1 and other components
of the endocannabinoid system were demonstrated in human
and rodent muscular tissue (Cavuoto et al., 2007b; Esposito et al.,
2008; Eckardt et al., 2009; Lipina et al., 2010; Crespillo et al.,
2011), in particular in the primary myotubes of skeletal muscle
and the rectus abdominis as well as in cultured rat muscular
cells (Lipina et al., 2010). Functionally, CB1 signaling in skeletal
muscle has a negative effect on the expression of genes regulating
oxidation and insulin sensitivity (Cavuoto et al., 2007a; Hardie,
2011), modulates the glucose/pyruvate/lactate pathways,
regulates mitochondrial dihydrolipoamide dehydrogenase
(Arrabal et al., 2015) and controls myoblast differentiation
(Iannotti et al., 2014). Therefore, the function and dysfunction
of the endocannabinoid system in muscle is a great focus of
research interest in order to better understand the underlying
mechanisms of metabolic disorders.
In the central nervous system (CNS), CB1 receptors are
localized on the plasma membrane of synaptic terminals,
but also in intracellular compartments (Rozenfeld and Devi,
2008; Bénard et al., 2012; Hebert-Chatelain et al., 2014a,b).
The anatomical localization and functional implication of CB1
Abbreviations: 2-AG: 2-arachidonoylglycerol; ATP: adenosine triphosphate;
BSA: bovine serum albumin; cAMP: cyclic adenosine monophosphate; CB1:
cannabinoid type 1 receptor; CB1-KO: lack of cannabinoid type 1 receptor;
CNS: central nervous system; DAGLα, DAGLβ: diacylglycerol lipase α, β; 19-
THC: delta-9-tetrahydrocannabinol; MAGL: monoacylglycerol lipase; mtCB1:
mitochondrial cannabinoid type 1 receptor; OCR: oxygen consumption ratio;
OsO4: osmium tetroxide; PB: phosphate buffer; PBS: phosphate-buffered saline;
PKA: protein kinase A; qRT-PCR: quantitative reverse transcription polymerase
chain reaction; RCR: respiratory coupling ratio; RT: room temperature; TBS:
Tris-HCl buffered saline; WT: wild type.
receptors on mitochondrial membranes (mtCB1) of brain cells
were demonstrated in our own (Bénard et al., 2012; Hebert-
Chatelain et al., 2014a,b) and in other laboratories (Koch et al.,
2015; Ma et al., 2015; see also Morozov et al., 2013, 2014;
Hebert-Chatelain et al., 2014a; Piomelli, 2014 for methodological
discussions). Thus, activation of brain mtCB1 receptors reduces
mitochondrial respiration and ATP production (Bénard et al.,
2012; Hebert-Chatelain et al., 2014a,b). In the hypothalamus,
activation of CB1 receptors negatively regulates leptin-induced
reactive oxygen species formation (Palomba et al., 2015) and
increases coupled mitochondria respiration that associates with
the generation of reactive oxygen species (Koch et al., 2015).
CB1 has also been shown in our laboratories to be present in
muscle mitochondria where it regulates mitochondrial oxidative
activity (Arrabal et al., 2015). However, a detailed anatomical
and functional characterization of mtCB1 in striated muscles is
still pending. The aim of this study was to investigate in detail
the distribution and functional role of mtCB1 in three different
striated muscles.
To investigate this, specific CB1 antibodies applied to two
skeletal muscles (gastrocnemius and rectus abdominis) and
myocardium of wild-type and knock-out mice, were combined
with a high resolution pre-embedding immunocytochemical
method for electron microscopy, followed by strict
quantification. Moreover, the impact of CB1 agonism on oxygen
consumption (respiration) of muscle purified mitochondria
from wild-type and CB1-KO mice was also analyzed.
MATERIALS AND METHODS
Animal Treatment
The procedures were carried out in accordance with European
Communities Council Directives (2003/65/CE and 2010/63/UE)
and current Spanish regulations (Real Decreto 53/2013 and Ley
32/2007). The protocols for animal care and use were approved
by the appropriate Committee at the University of the Basque
Country UPV/EHU (CEBA/93/2010/GRANDESMORENO).
Furthermore, great efforts were made in order to minimize the
number and suffering of the animals used.
6 wild-type C57BL/6N female mice (3–5 month old)
and 3 CB1-KO female mice were used. CB1-KO mice were
obtained, bred and genotyped as described (Marsicano et al.,
2002). The line was in a mixed genetic background, with a
predominant C57BL/6N contribution. Animals were maintained
under standard conditions (12 h light/dark cycle) with food
(standard chow, Global Diet 2014S, Harlan) and water ad
libitum. During the light cycle, mice were deeply anesthetized by
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intraperitoneal injection of ketamine/xilazine (80/10mg/kg body
weight) and were transcardially perfused at room temperature
(RT, 20–25◦C) with phosphate-buffered saline (PBS 0.1M, pH
7.4) for 20 s, followed by the fixative solution made up of 4%
formaldehyde (freshly depolymerized from paraformaldehyde),
0.2% picric acid and 0.1% glutaraldehyde in a phosphate buffer
(PB 0.1M, pH 7.4) for 10–15min. Then, muscles (rectus
abdominis, gastrocnemius and myocardium) were removed and
postfixed in the fixative solution for approximately 1 week at 4◦C.
Afterwards, they were stored at 4◦C in a 1:10 diluted fixative
solution until used.
Preembedding Immunogold Method for
CB1 Immunoelectron Microscopy
Muscular tissues were cut at 50 µm in a vibratome and
collected in 0.1M PB (pH 7.4) at RT. Sections were preincubated
in a blocking solution of 10% bovine serum albumin BSA,
0.1% sodium azide and 0.02% saponin prepared in TBS (1X,
pH 7.4) for 30min at RT. A preembedding silver-intensified
immunogold method was used for the localization of the CB1
protein. Muscular sections were incubated in the primary goat
CB1 polyclonal antibodies (2µg/ml; CB1-Go-Af450-1; Frontier
Science Co. Ltd; 1-777-12, Shinko-nishi, Ishikari, Hokkaido,
Japan) in 10% BSA/TBS containing 0.1% sodium azide and
0.004% saponin on a shaker for 2 days at 4◦C.
After several washes in 1% BSA/TBS, tissue sections were
incubated in a secondary 1.4 nm gold-labeled rabbit anti-goat
IgG (Fab’ fragment, 1:100, Nanoprobes Inc., Yaphank, NY, USA)
in 1% BSA/TBS with 0.004% saponin on a shaker for 4 h at
RT. Thereafter, the tissue was washed in 1% BSA/TBS, stored
overnight at 4◦C and postfixed in 1% glutaraldehyde in TBS for
10min at RT. Following the washes in double-distilled water, gold
particles were silver-intensified with a HQ Silver kit (Nanoprobes
Inc., Yaphank, NY, USA) for about 12min in the dark and then
washed in 0.1M PB (pH 7.4). Stained sections were osmicated
(1% OsO4 in 0.1M PB, pH 7.4, 20min), dehydrated in graded
alcohols to propylene oxide and plastic-embedded flat in Epon
812. 65 nm ultrathin sections were collected onmesh nickel grids,
stained with uranyl acetate and lead citrate, and examined in a
Philips EM208S electron microscope. Tissue preparations were
photographed by using a digital camera coupled to the electron
microscope.
Semi-quantification of Mitochondrial CB1 in Muscle
Fifty micrometer-thick muscular sections from each animal
genotype (n = 3 each) were cut at 65 nm and random
electron micrographs (10,000–25,000X) were taken from the
grids (132µm side). To avoid false negatives, only ultrathin
sections in the first 1.5µm from the surface of the tissue
block were examined. Positive labeling was considered if
at least one immunogold particle was over mitochondria
or within approximately 30 nm from the mitochondria
membrane. Metal particles on mitochondrial membranes were
visualized and counted by unbiased observers. The numbers of
labeled mitochondria were normalized to the total number of
mitochondria in the images in order to establish the proportion of
CB1-positive mitochondria. Normalized mtCB1 labeling versus
total CB1 defined the proportion of mtCB1 versus total CB1
as performed previously (Bénard et al., 2012; Hebert-Chatelain
et al., 2014a). Density of mitochondrial CB1 immunolabeling
was calculated as immunoparticles/µm membrane of positive
mitochondria. Image-J software (1.43u version, NIH, USA) was
used to measure the membrane length and analyzed area. Values
within wild-type or CB1-KO littermates did not show any
significant difference, allowing the pooling of respective wild-
type and CB1-KO littermates.
Mitochondrial Isolation from Heart and
Mitochondrial Respiration
Mitochondria were isolated from the heart of the mice by
differential centrifugation. Hearts were collected in isolation
medium I (in mM: 210 mannitol, 70 sucrose, 50 Tris-HCl, pH
7.4, and 10 K-EDTA), finely cut and then digested by trypsin
(0.5mg/g of heart muscle) for 30min. The proteolysis was
stopped by addition of trypsin inhibitor (soybean 3:1 inhibitor to
trypsin). Tissues were homogenized using a tissue homogenizer.
The homogenate was centrifuged at 1000 g for 5 min. The
supernatant was strained through gauze and centrifuged at
7000 g for 10min. The resulting pellet was resuspended in ice-
cold isolation medium II (in mM: 225 mannitol, 75 sucrose,
10 Tris-HCl, pH 7.4, and 0.1 K-EDTA), and a new series
of centrifugations (1000 and 7000 g) was performed. The last
mitochondrial pellet was resuspended into a minimum volume
of isolation medium II to obtain a mitochondrial concentration
between 10 and 40mg/ml.
Mitochondrial oxygen consumption ratio (OCR) was
monitored at 37◦C. Isolated mitochondria were placed in an
oxygraph chamber equipped with a Clark oxygen electrode
(Hansatech) containing 1ml of respiration buffer (75mM
mannitol, 25mM sucrose, 100mM KCl, 10mM Tris phosphate,
10mM Tris-HCl, pH 7.4, 5mM EDTA). The final mitochondrial
concentration in the chamber was 1mg/ml. The respiratory
states were obtained by adding consecutively to the chamber
Pyruvate and Malate at 10mM final (state 4) and then, ADP at
2 mM (state 3). THC was added directly into the respiratory
chamber (final concentration 100 and 200 nM) during state 3.
Oxygen concentration in the chamber was recorded over the
time and effect of THC on the OCR was measured between
5 and 10 min after the THC addition. Respiration rates
were normalized to protein concentration. The respiratory
coupling ratio (RCR) was defined as the ratio of state 3 over
state 4.
Immunoprecipitation
Immunoprecipitation of CB1 was performed on the
mitochondrial fraction isolated as described above by
using the PierceTM Co-Immunoprecipitation Kit, as per
manufacturer’s instructions. Briefly, the mitochondrial
fraction (625µg of protein) were diluted in IP/lysis buffer
and pre-cleared using a control agarose resin to minimize
non-specific binding. These lysates were then applied to
columns containing 8µg immobilized anti-CB1 (Abcam,
ab23703) covalently linked to an amine-active resin and
incubated overnight at 4◦C. The immunoprecipitate was
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FIGURE 1 | subcellular localization of CB1 receptors in mitochondria of striated muscles. Preembedding silver-intensified immunogold method for electron
microscopy. CB1 immunoparticles (arrows) are localized in outer mitochondrial (mt) membranes of the gastrocnemius (A), rectus abdominis (C) and myocardial (E)
muscles of CB1-WT mice. No labeling is observed in mitochondria (mt) of CB1-KO muscles (B,D,F). Scale bars: 0.5µm. All electron micrographs were taken at the
same magnification (x 22,000).
then eluted, mixed with Laemmli buffer, heated to 37◦C
for 30min and analyzed by SDS-PAGE using conventional
methods.
RNA Isolation and qRT-PCR Analysis
Total RNAwas extracted from striated (rectus abdominis) mouse
muscle (∼100 mg) by using the Trizol method, as previously
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TABLE 1 | Primer references for TaqMan® gene expression assays
(ThermoFisher).
Gene name Assay ID Amplicon length
Actb Mm00607939_s1 115
Gapdh Mm99999915_g1 109
Gusb Mm01197698_m1 71
Eno3 Mm00468267_m1 54
Pkm2 Mm00834102_gH 182
Pdha1 Mm00468675_m1 74
Sdha Mm01352366_m1 82
Cox4i1 Mm01250094_m1 116
Actb, β-actin; Cox4i1, cytochrome c oxidase subunit 4 isoform 1, mitocondrial; Eno3,
enolase 3, β-muscle; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; Gusb, β-
glucuronidase; Pdha1, pyruvate dehydrogenase E1 alpha 1; Pkm2, pyruvate kinase,
muscle isozyme; Sdha, succinate dehydrogenase complex, subunit A, flavoprotein
variant.
described (Arrabal et al., 2015). Purified RNA (1µg) and
random hexamers were used to generate first strand cDNA using
transcriptor reverse transcriptase. cDNA was used as a template
for quantitative real-time PCR. The relative quantification was
normalized to the expression of the housekeeping gene Gapdh
and calculated by using the 11Ct method. Primers used for
the qRT-PCR reaction were obtained based on TaqMan R© Gene
Expression Assays (Life Technologies) (Table 1).
Statistical Analysis
Results were expressed as mean ± S.E.M. of 3–6 determinations
per experimental group. For semi-quantification of
mitochondrial CB1, group differences were compared by the chi-
square test. For density of mitochondrial CB1 immunolabeling,
group differences were analyzed by the Mann Whitney test.
For gene expression, group differences were analyzed by one-
tailed Student’s t-test with the Welch correction. A P-value
below 0.05 was considered statistically significant. Graphs and
statistical analyses were performed using GraphPad software
4.0 (GraphPad Software Inc., San Diego, USA). Oxygen
consumption measurements: statistics were performed using
GraphPad Prism6. Values are means ± S.E.M. Paired t-test
was used when comparing sequential measurements. One-way
ANOVA followed by Sidak multiple comparison test were
applied when comparing different groups.
RESULTS
Immunolocalization of Mitochondrial CB1
in Muscle
The subcellular compartmentalization of CB1 in three different
striated muscle tissues of mice by using a preembedding
immunogold method for electron microscopy was studied. The
gastrocnemius had CB1 immunoparticles along the sarcolemma
of the muscle fibers. Only scattered immunoparticles were
observed at the limits of the sarcomer as well as in the
sarcoplasmic reticulum. However, the greatest accumulation of
immunoparticles was in the mitochondria (Figure 1). About
FIGURE 2 | proportion of CB1 immunopositive mitochondria. (A) Values
obtained in the gastrocnemius (25.77 ± 1.02%), rectus abdominis (21.29 ±
0.98%) and myocardium (17.24 ± 1.29%) of 3 different mice. These values are
very low in CB1-KO muscles (gastrocnemius: 0.37 ± 0.04%; rectus
abdominis: 1.45 ± 0.29%; myocardium: 2.79 ± 0.57%). Numbers between
parentheses indicate the number of analyzed profiles. Values mean ± S.E.M.
Chi-square test. ***P < 0.001 as compared to CB1-WT. (B) Density of CB1
gold particles per area (µm2) of the immunopositive mitochondria in
gastrocnemius (21.49 ± 2.51%), rectus abdominis (16.25 ± 1.95%) and
myocardium (3.30 ± 0.60%) of CB1-WT. ***P < 0.001. Numbers between
parentheses indicate the number of analyzed profiles. Density was negligible in
CB1-KO, therefore, it was not taken into account to avoid distorting bias. (C)
Proportion of CB1 immunoparticles in mitochondria of the total CB1 labeling in
gastrocnemius (60 ± 1.73%), rectus abdominis (55.04 ± 1.15%) and
myocardium (78.11 ± 1.16%) drops drastically in CB1-KO muscles.
26% of the mitochondria in the gastrocnemius were CB1
immunopositive (25.77% ± 1.022, n = 644) with the majority
of gold particles disposed on the outer mitochondrial membrane
(Figures 1A, 2A). Importantly, CB1 staining was virtually absent
in the gastrocnemius of mice lacking CB1 (CB1-KO, Figure 1B),
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since only a fewmitochondria (0.37%± 0.040, n= 536) exhibited
occasional unspecific background particles (Figure 2A).
A similar distribution pattern of CB1 immunostaining
was observed in the other muscles studied. Thus, in the
rectus abdominis (Figures 1C,D), the proportion of CB1
immunopositive mitochondria was slightly lower than in the
gastrocnemius (21.29% ± 0.982, n = 584) and the background
level was estimated to be below 1.5% in the CB1-KO (1.45% ±
0.289, n = 538) (Figure 2A). Also, the CB1 immunolocalization
in the myocardium (Figures 1E,F) was predominantly in
mitochondria (17.24% ± 1.293, n = 522) with a background of
∼2.8% in the CB1-KO (2.79% ± 0.571, n = 501) (Figure 2A).
Taken together, the mtCB1 labeling seems to be highly specific
in the three muscles because the percentage of mitochondria
with residual staining was negligible in the same muscles of
CB1-KO mice processed simultaneously with CB1-WT muscle
tissues. Furthermore, the density of CB1 immunolabeling, i.e.,
the number of gold particles per square micron of labeled
mitochondrial membrane, was 21.49 ± 2.51 (n = 166) in the
gastrocnemius, 16.25 ± 1.95 (n = 124) in the rectus abdominis
and 3.30 ± 0.60 (n = 90) in the myocardium (Figure 2B).
Lastly, 60 ± 1.7% of the gastrocnemius, 55 ± 1.16% of the
rectus abdominis and 78 ± 1.16% of the myocardium total
CB1 immunoparticles were localized to mitochondria and almost
null in CB1-KO (Figure 2C), indicating that the predominant
distribution of CB1 in the analyzed muscles is in this organelle.
Functional Assays of Mitochondrial CB1 in
Muscle
The regulation of mitochondrial bioenergetic functions by CB1
receptors was also investigated. Mitochondrial respiration was
measured on heart mitochondria isolated from both wild-
type and CB1-KO mice. The focus was on the myocardium
because this muscle had the highest proportion of CB1
in the mitochondria. There was no difference between KO
and wild-type isolated mitochondria regarding basal and
coupled respiration (respectively State 4 and State 3; see
Table 2) and no difference was found regarding the respiratory
coupling ratio (State3/State4). Together, these results showed
that both wild-type and KO isolated mitochondria had the
same capacity to produce ATP. Yet, acute THC treatment
specifically inhibited mitochondrial oxygen consumption in
wild-type isolatedmitochondria. Adding 100 nMor 200 nMTHC
respectively decreased the mitochondria coupled respiration
by 11.9 ± 3.7% and 15.2 ± 1.3% compared to the vehicle
(n = 4) (Figure 3A left graph, CB1-WT; Figure 3B). In contrast,
TABLE 2 | Basal (State 4) and coupled (State 3) respiration in isolated
Mitochondria.
OCR (nMol Oxygen/min/mg prot.) CB1–WT CB1–KO
Pyruvate+Malate (State 4) 33.54±4.03 38.52± 5.06
Pyruvate+Malate+ADP (State 3) 122.08±16.21 132.05± 16.24
Coupling ratio 3.75±0.43 3.50± 0.26
Absolute value (means ± SEM, n = 6). Differences are non-significative.
no significant difference was noticed between THC treated
and vehicle in mitochondria isolated from CB1-KO heart
(Figure 3A right graph, CB1-KO; Figure 3B). As a control,
immunoprecipitation was performed to test for the presence
of CB1 in the mitochondrial fractions. The protein extracts
from CB1-WT and CB1-KO heart mitochondria fractions were
subjected to immunoprecipitation with an antibody against
CB1, and subsequently analyzed through Western blotting.
Representative results demonstrate that CB1 was precipitated
from the CB1-WT mitochondrial fraction but not from the CB1-
KO fraction (Figure 3C).
Gene Expression of Relevant Enzymes in
Pyruvate Metabolism, TCA Cycle and
Mitochondrial Respiratory Chain in the
Striated Muscle
To further investigate the mitochondrial energetic functions,
the gene expression of key enzymes involved in pyruvate
synthesis, TCA cycle and mitochondrial respiratory chain in the
rectus abdominis of CB1-WT and CB1-KO mice was evaluated
(Figure 4). CB1-KO mice showed an increase in the gene
expression of Eno3, Pkm2, and Pdha1 (∗P < 0.05), suggesting
an increased production of pyruvate, a main substrate of TCA
cycle activity. In contrast, no significant difference was observed
in the muscle expression of Sdha and Cox4i1 between CB1-WT
and CB1-KO mice (Figure 4).
DISCUSSION
Following our previous observations in rat and mouse (Arrabal
et al., 2015) these data confirm and further extend the
presence of CB1 in mitochondria of the mouse striated skeletal
(gastrocnemius and rectus abdominis) and myocardial muscles.
In particular, CB1 immunoparticles were localized on the outer
mitochondrial membrane similarly to the mtCB1 distribution in
the CB1-WT hippocampus, with almost absent mtCB1 in CB1-
KO tissue (Bénard et al., 2012; Hebert-Chatelain et al., 2014a,b).
Indeed, about 30% of the mitochondria in axon terminals and
somatodendritic domains of neurons contained CB1 in the
hippocampal CA1 region of CB1-WT, with a background of
3% in CB1-KO (Bénard et al., 2012). Although mtCB1 labeling
has been challenged by using the DAB-Ni technique (Morozov
et al., 2013, 2014, 2016) that produces a higher background
mitochondrial staining than the immunogold procedure due to
the presence of endogenous biotinylated proteins (Hollinshead
et al., 1997; Bénard et al., 2012; Hebert-Chatelain et al.,
2014a,b), careful quantifications revealed a significantly higher
staining of brain mitochondria in wild-type than in CB1-KO
brain tissue, regardless of the method used (Bénard et al.,
2012; Hebert-Chatelain et al., 2014a,b). Furthermore, with a
very restrictive quantification protocol, i.e., taking into account
only mitochondrial particles far away from other neuronal
membranes, about 22% of the mitochondrial sections were CB1
immunopositive in CB1-WT and only 3% exhibited particles
in the CB1-KO hippocampal tissue (Hebert-Chatelain et al.,
2014a,b).
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FIGURE 3 | (A) Effect of THC on heart isolated mitochondria. THC (100 nM or 200 nM, gray bars) or vehicle (white bars) was added directly to the respiratory chamber
during the ADP-dependent respiration. Values are expressed as mean of percentage of the ADP-dependent respiration of CB1-WT (left panel) or CB1-KO (right panel)
isolated mitochondria (n = 4). (B) Difference of inhibition between vehicle and THC dependent respiration (White bars; CB1-WT, Black bars CB1-KO). *P < 0.05 THC
vs. VEH; **P < 0.01 THC vs. VEH; ***P < 0.001 THC vs. VEH; #P < 0.05 CB1-WT vs. CB1-KO. C) Immunoprecipitation of CB1 from heart mitochondrial fractions of
CB1-WT or CB1-KO.
FIGURE 4 | Gene expression of Eno3, Pkm2, Pdha1, Sdha and Cox4i1
in the striated muscle of CB1-WT and CB1-KO mice. Student’s t-test
(n = 6): *P < 0.05 vs. wild-type.
The amount of mitochondria in striated muscles is more
abundant than in the brain because the energy demand in muscle
cells and cardiomyocytes is very high. Furthermore, the size,
shape and number of mitochondria are constantly changing
as a consequence of muscle and heart activity. Therefore, the
distribution of CB1 receptors may depend on the quantity of
muscle mitochondria. The results of this study showed that
the proportion of mitochondrial sections equipped with CB1
in the muscle was in the range of the brain, indicating that
only a certain subpopulation of mitochondria bearing CB1
receptors is present in both the CNS and the peripheral striated
muscles. Furthermore, the immunolabeling density in the CA1
hippocampus was around 18 particles/µm2 and around 15% of
the total CB1 immunolabeling in CA1 neurons was localized in
the mitochondria (Bénard et al., 2012). In muscles, the density
was only low in myocardium and the proportion of the total CB1
immunoparticles in the mitochondria was between 55 and 78%
in the three muscle samples studied, pointing out that despite its
low absolute level of expression in the myocardium, but not in
the others (Pagotto et al., 2006), the majority of CB1 receptors
in the muscle is present on mitochondrial membranes. In the
brain, the activation of mtCB1 receptors induces a reduction
of mitochondrial respiration of about 20–30% (Bénard et al.,
2012; Hebert-Chatelain et al., 2014a,b). Similarly, THC activation
of the CB1 receptors in the myocardium mitochondria reduces
mitochondrial respiration, although at a lower rate than in the
brain. This difference may be explained, among other factors,
by the lower amount of CB1 receptors (particle density and
percentage of positive mitochondria) in the myocardium as
compared to the brain, which cannot be compensated by the
fact that the vast majority of the total CB1 immunoparticles in
myocardium are localized in mitochondria.
The two skeletal muscles analyzed, the gastrocnemius and
the rectus abdominis, are enriched in type I slow-twitch
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oxidative fibers (Hijikata et al., 1992). Therefore, a potential
role for mtCB1 receptors might be the regulation of the
oxidative activity at the mitochondria, probably through the
relevant enzymes Eno3 and Pkm2, which are implicated in
the pyruvate metabolism (a main substrate for TCA cycle),
as well as the Pdha and DLD, which are key components
of the mitochondrial pyruvate/α-ketoglutarate/branched-chain
keto acid (BCKDC) dehydrogenase complexes implicated in
the TCA cycle activity (Arrabal et al., 2015). In fact, studies
using a CB1 receptor antagonist (Rimonabant) demonstrated
that a blockade of cannabinoid receptors increases glucose use
by striated muscle (Liu et al., 2005; Cavuoto et al., 2007a).
Moreover, a previous study indicated that it is mandatory
the abetment of a hypercaloric context and a deficiency in
CB1 receptor activity to observe an increased expression of
the mitochondrial respiratory chain component Cox4i1 and
a potential mitochondrial respiration (Arrabal et al., 2015).
Together these results indicated an up-regulation of the
glucose/pyruvate metabolism in response to increased energy
expenditure through mitochondrial oxidation and TCA cycle
in the insulin-highly sensitive striated muscle. However, the
transcriptional differences in pyruvate metabolism could not
reflect changes in the maximal capacity of ATP production,
suggesting no evident differences in the basal phenotype of
the CB1-KO muscle at functional levels. Indeed, we have not
found any change in the gene expression of the mitochondrial
respiratory chain factors Sdha (complex II) and Cox4i1 (complex
IV) or in the mitochondrial oxygen consumption rate between
genotypes. Considering these findings, we suggest that the
increased redox activity after CB1 receptor blockade (Arrabal
et al., 2015) is likely produced in response to buffer a putative
increase in reactive oxygen species. A buffered redox state under
basal conditions could be one of the reasons for the lack of
differences in mitochondrial respiration between genotypes, but
can be challenged under an energy imbalance.
As the functional significance, the activation of CB1 receptors
localized in different body tissues (brain, liver, skeletal muscle,
pancreas, adipose tissue) participates in cellular and metabolic
functions of the organism (Piomelli, 2003; Silvestri and Di
Marzo, 2013; Iannotti et al., 2014; Mazier et al., 2015; Palomba
et al., 2015) and regulates the mitochondrial biogenesis in non-
neuronal peripheral tissues (Aquila et al., 2010; Tedesco et al.,
2010). There are pieces of evidence indicating that mitochondria
contain G proteins (Lyssand and Bajjalieh, 2007; Andreeva et al.,
2008) and their effector signaling molecules such as soluble
adenyl cyclase (Zippin et al., 2003), phosphodiesterase (Acin-
Perez et al., 2011) and protein kinase A (PKA) (Ryu et al.,
2005). Hence, cAMP generated in the mitochondria would lead
to PKA activation and protein phosphorylation, thus regulating
mitochondrial respiration and energy production (Chen et al.,
2004; Helling et al., 2008; Acin-Perez et al., 2011). The oxidative
phosphorylation carried out in mitochondria transforms the
energy of the nutrients into ATP. The mitochondria regulate
important physiological processes constantly adapting structure
and functions to maintain the cellular metabolic homeostasis. In
fact, mitochondria dysfunction is involved in neurodegenerative
diseases obesity, insulin resistance and type 2 diabetes (Højlund
et al., 2008; Bournat and Brown, 2010; Sivitz and Yorek, 2010;
Dietrich et al., 2013; Schneeberger et al., 2013).
The skeletal muscle is the primary organ for nutrients and
fatty acids oxidation, as well as glucose uptake. Insulin resistance
is associated with a loss of muscular oxidative capacity in
response to an increase of intake of fat-rich foods (Cavuoto
et al., 2007a). The insulin resistance plays an important role in
the pathogenesis of the metabolic syndrome and type 2 diabetes
(Kelley et al., 2002; Kelley, 2005), while the blocking of CB1
receptors in the skeletal muscle has a direct effect on energy
expenditure and oxidative metabolism (Ravinet Trillou et al.,
2003; Liu et al., 2005; Arrabal et al., 2015). Skeletal muscle cells
have been shown to contain CB1 and CB2 receptors as well as
the endocannabinoid enzymatic machinery (DAGLα, DAGLβ,
and MAGL) (Crespillo et al., 2011), and also the localization of
CB1 receptors in striated muscle mitochondria was identified
(Arrabal et al., 2015). These observations altogether support
an endocannabinoid regulation of genes controlling the skeletal
muscle metabolism (Crespillo et al., 2011). Therefore, it is
presumable that the opposite effects of endocannabinoids and
CB1 agonists reducing mitochondrial function in metabolically
active tissues (Tedesco et al., 2010), and of CB1 antagonism
(Tedesco et al., 2008), are through CB1 receptors in the
mitochondria.
In conclusion, CB1 receptors are localized in the
mitochondria of striated muscles in a similar proportion to
brain tissue. Interestingly, most of the CB1 receptors in the
gastrocnemius, the rectus abdominis and the myocardium
are distributed in the mitochondria, in contrast to the
brain where they are preferentially localized in neuronal
membranes (Freund et al., 2003; Kano, 2014; Di Marzo et al.,
2015). Furthermore, the activation of the mitochondrial
CB1 receptors in striated muscle may participate in the
regulation of the oxidative activity at the muscle mitochondria
probably through the relevant enzymes implicated in the
pyruvate metabolism, a main substrate for the Krebs cycle
activity.
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